Prospecto:information for the user
Febuxostat cinfamed 120 mg film-coated tablets
Read this prospectus carefully before starting to take this medicine,because it contains important information for you.
If you have any doubts, consult your doctor or pharmacist.
-This medicine has been prescribedonlyto you, and you must not give it to other people evenifthey havethe same symptomsas you,as it may harm them.
1.What is Febuxostat cinfamed and what is it used for
2.What you need to knowbeforestarting totake Febuxostat cinfamed
3.How to take Febuxostat cinfamed
4.Possible adverse effects
5Storage of Febuxostat cinfamed
6.Contents of the package and additional information
This medicationcontains the active ingredient febuxostat and is used to treat gout, which is associated with an excess in the body of a chemical compound called uric acid (urate). In some people, uric acid accumulates in the blood to the point where it cannot be dissolved. When this occurs, urate crystals form both inside and around the joints and kidneys. These crystals can cause sudden and intense pain, redness, heat, and swelling in the joints (known as gout attacks). If left untreated, large deposits called tophi can form around the joints and inside them. Tophi can damage the joints and bones.
This medicationacts by reducing the concentration of uric acid. Maintaining low uric acid levels by takingFebuxostat cinfamedonce a day slows the formation of crystals and, over time, reduces symptoms. If uric acid levels are kept low for a sufficient period, the size of the tophi also decreases.
Febuxostat cinfamed120 mg tablets are also used in the treatment and prevention of high levels of uric acid in the blood, which can occur when chemotherapy is started to treat blood cancer.
When chemotherapy is administered, cancer cells are destroyed, and as a result, uric acid levels in the blood decrease, unless its formation is prevented.
This medicationis for adults.
Do not takeFebuxostat cinfamed:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Febuxostat cinfamed:
If you experience allergic reactions to Febuxostat cinfamed, stop taking this medication (see also section 4). Possible symptoms of allergic reactions may be:
Your doctor may decide to permanently discontinue febuxostat treatment.
Rare cases of life-threatening skin eruptions (Stevens-Johnson syndrome) have been reported with the use of febuxostat, initially appearing on the trunk as red spots in the shape of a bull's-eye or circular spots often with a blister in the center. It may also include mouth ulcers, throat, nose, genital, and conjunctivitis (red and swollen eyes). The rash may evolve into generalized blisters or skin peeling.
If you have developed Stevens-Johnson syndrome with the use of febuxostat, do not restart febuxostat treatment at any time.If you develop a rash or these skin symptoms, go immediately to your doctor and tell them that you are taking this medication.
If you experience a gout attack (a sudden, intense pain accompanied by sensitivity, redness, heat, and swelling of a joint), wait for the attack to subside before starting febuxostat treatment.
Some people may experience a gout attack when starting certain medications that control uric acid levels. Not everyone experiences these attacks, but they can occur even while taking febuxostat, especially during the first weeks or months of treatment. It is essential to continue taking febuxostat daily, as this medication continues to act to reduce uric acid levels. If you continue to take febuxostat, gout attacks will become less frequent and less painful.
If necessary, your doctor will prescribe other medications to prevent or treat gout attack symptoms (such as joint pain and swelling).
In patients with very high uric acid levels (e.g. those undergoing chemotherapy for cancer), treatment with medications to reduce uric acid levels may lead to the accumulation of xanthine in the urinary tract, with possible stone formation, although this has not been observed in patients treated with febuxostat for tumor lysis syndrome.
Your doctor may perform blood tests to check that your liver is functioning normally.
Children and adolescents
Do not administer this medication to children under 18 years of age, as the safety and efficacy have not been established.
Other medications and Febuxostat cinfamed
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication, including those purchased without a prescription.
It is especially important to inform your doctor or pharmacist if you are using medications containing any of the following substances, as they may interact with febuxostat, and your doctor may need to take special measures:
Pregnancy, breastfeeding, and fertility
It is not known if this medication can harm the fetus. Febuxostat should not be used during pregnancy. It is not known if febuxostat passes into breast milk. Do not use this medication if you are breastfeeding or planning to breastfeed.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
Be aware that you may experience dizziness, drowsiness, blurred vision, numbness, or tingling during treatment, so if this occurs, do not drive or operate machinery.
Febuxostat cinfamed contains lactose and sodium
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Gout
This medication is marketed in tablets of 80 mg and 120 mg. Your doctor will prescribe the most suitable dose.
Continue taking febuxostat every day, even if you no longer have a gout attack.
Prevention and treatment of high uric acid levels in patients undergoing chemotherapy for cancer
Start taking febuxostat two days before chemotherapy and continue using it as indicated by your doctor. Generally, the treatment is of short duration.
If you take more Febuxostat cinfamed than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Febuxostat cinfamed
If you forget a dose of febuxostat, take it as soon as you remember, unless it is almost time to take the next one; in that case, skip the missed dose and take the next one at the usual time. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Febuxostat cinfamed
Although you may be feeling better, do not stop taking febuxostat, unless your doctor tells you to. If you stop taking febuxostat, the uric acid concentration may increase again, and symptoms may worsen due to the formation of new urate crystals in the joints and kidneys.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking this medicine and contact your doctor immediatelyor go to the nearest hospital if you experience any of the following rare side effects (may affect up to 1 in 1000 people), as you may experience a severe allergic reaction:
Thefrequent side effects(may affect up to 1 in 10 people) are:
Other side effects not mentioned above are included below.
Theinfrequent side effects(may affect up to 1 in 100 people) are:
Therare side effects(may affect up to 1 in 1000 people) are:
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly throughthe Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears onthe carton box and on the blister packafter CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Febuxostat cinfamed
Each Febuxostat cinfamed tablet contains 120 mg of febuxostat.
Appearance of Febuxostat cinfamed and contents of the package
Yellow-coated, biconvex, capsule-shaped tablets with “F 20” engraved on one face and smooth on the other.
The box contains PVC/PE/PVdC blisters and an aluminum sheet.
It is available in packages of 28 and 84 coated tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10 Industrial Estate Areta
31620 Huarte (Navarra) – Spain.
Responsible for manufacturing
Macleods Pharma UK Limited
Wynyard Park House,
Wynyard Avenue,
Wynyard, Billingham,
TS22 5TB
United Kingdom
or
Synoptis Industrial Sp. z o.o.
ul. Rabowicka 15,
62-020Swarzedz, Poland
or
Heumann Pharma GmbH & Co. Generica KG,
Südwestpark 50, 90449 Nürnberg,
Germany
This medicine is authorized in the member states of the European Economic Area with the following names:
United Kingdom - Febuxostat 120 mg film-coated tablets
Germany - Febuxostat Heumann 120 mg Filmtabletten
Last review date of this prospectus:September 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
https://cima.aemps.es/cima/dochtml/p/83403/P_83403.html
QR code to:https://cima.aemps.es/cima/dochtml/p/83403/P_83403.html
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.